On 'evidence'

Same author

In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity.

Journal of enzyme inhibition and medicinal chemistry·2026

Same author

Synthesis of N-Acetyl-D- and -L-Leucine-13C6 Tool Compounds in Neurodegenerative Disease.

ChemMedChem·2026

Same author

Targeting the p53 cancer mutants Y220C, Y220N, and Y220S with the small-molecule stabilizer rezatapopt.

Cell death & disease·2026

Same author

The dihydropyridine LA1011 modulates multiple Hsp90-co-chaperone interactions relevant to Alzheimer's disease.

Cell stress & chaperones·2025

Same author

Removal of Toxic Metabolites-Chelation: Manganese Disorders.

Journal of inherited metabolic disease·2025

Same author

Knowing Me Knowing You-Mentorship in Hospital Placement.

The clinical teacher·2025

Same journal

Channelling Socrates to re-imagine asynchronous online learning.

Medical education·2026

Same journal

Moving beyond tokenism: A structured and intentional approach to embedding health advocacy in medical education.

Medical education·2026

Same journal

When I say … 'in situ simulation'.

Medical education·2026

Same journal

Examiner training and calibration for simulated clinical examinations: A scoping review.

Medical education·2026

Same journal

When systems set the limits of supervision.

Medical education·2026

Same journal

From psychometrics to partnerships: Broadening what counts as validity evidence.

Medical education·2026

Related Experiment Videos

On 'evidence'

Related Concept Videos

<i>In vitro</i> screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives <i>CDKN1</i> and <i>BBC3</i> expression to restore a p53-dependent cytotoxicity.

Synthesis of N-Acetyl-D- and -L-Leucine-<sup>13</sup>C<sub>6</sub> Tool Compounds in Neurodegenerative Disease.

Targeting the p53 cancer mutants Y220C, Y220N, and Y220S with the small-molecule stabilizer rezatapopt.

The dihydropyridine LA1011 modulates multiple Hsp90-co-chaperone interactions relevant to Alzheimer's disease.

Removal of Toxic Metabolites-Chelation: Manganese Disorders.

Knowing Me Knowing You-Mentorship in Hospital Placement.

Channelling Socrates to re-imagine asynchronous online learning.

Moving beyond tokenism: A structured and intentional approach to embedding health advocacy in medical education.

When I say … 'in situ simulation'.

Examiner training and calibration for simulated clinical examinations: A scoping review.

When systems set the limits of supervision.

From psychometrics to partnerships: Broadening what counts as validity evidence.

Related Experiment Videos

On 'evidence'

Related Concept Videos

Related Articles

<i>In vitro</i> screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives <i>CDKN1</i> and <i>BBC3</i> expression to restore a p53-dependent cytotoxicity.

Synthesis of N-Acetyl-D- and -L-Leucine-<sup>13</sup>C<sub>6</sub> Tool Compounds in Neurodegenerative Disease.

Targeting the p53 cancer mutants Y220C, Y220N, and Y220S with the small-molecule stabilizer rezatapopt.

The dihydropyridine LA1011 modulates multiple Hsp90-co-chaperone interactions relevant to Alzheimer's disease.

Removal of Toxic Metabolites-Chelation: Manganese Disorders.

Knowing Me Knowing You-Mentorship in Hospital Placement.

Channelling Socrates to re-imagine asynchronous online learning.

Moving beyond tokenism: A structured and intentional approach to embedding health advocacy in medical education.

When I say … 'in situ simulation'.

Examiner training and calibration for simulated clinical examinations: A scoping review.

When systems set the limits of supervision.

From psychometrics to partnerships: Broadening what counts as validity evidence.